Search Results for "Hematologic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hematologic. Results 81 to 90 of 101 total matches.

Two New Drugs for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
and/ or longer treatment durations might increase the risk of hematologic abnormalities with tedizolid ...
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ). Tedizolid phosphate (Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox). A third IV antibiotic, oritavancin (Orbactiv), recently approved by the FDA for the same indication, will be reviewed in a future...
Med Lett Drugs Ther. 2014 Aug 18;56(1449):73-5 |  Show IntroductionHide Introduction

Choice of Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990  (Issue 832)
, diarrhea, pseudomembranous colitis, and transient disturbances in hepatic, renal, and hematological ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Med Lett Drugs Ther. 1990 Nov 30;32(832):107-10 |  Show IntroductionHide Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020  (Issue 1600)
the likelihood of hematologic and GI toxicity. 8. Baseline thiopurine methyltransferase (TPMT) testing ...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 |  Show IntroductionHide Introduction

Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
, renal or hepatic impairment, or hematologic disorders. Frailty, advanced age, and residence in a long ...
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6   doi:10.58347/tml.2023.1686a |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
reactions, new-onset psoriasis, hematologic cytopenias, non-ischemic congestive heart failure ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Table: Treatments Considered for COVID-19 (Archived) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020  (Issue 1595)
Hematologic toxicity may be additive with other drugs such as linezolid, clozapine, or azathioprine ...
View the Table: Treatments Considered for COVID-19
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289 |  Show IntroductionHide Introduction

Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
likely to occur in older patients and in those with renal impairment. Neutropenia and other hematologic ...
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24;60(1556):153-7 |  Show IntroductionHide Introduction

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
Effects – Ribavirin can cause gastrointestinal, musculoskeletal, hematologic, and dermatologic adverse ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Drugs for Pneumonia

   
Treatment Guidelines from The Medical Letter • Sep 01, 2003  (Issue 13)
, pain at intramuscular injection sites, and transient disturbances in hepatic, renal and hematologic ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Treat Guidel Med Lett. 2003 Sep;1(13):83-8 |  Show IntroductionHide Introduction

Chemotherapy for Esophageal, Gastric and Colorectal Cancers

   
Treatment Guidelines from The Medical Letter • Aug 01, 2006  (Issue 48)
-threatening non-hematologic toxicity. ECF may be less toxic than either FUP or TCF. COLORECTAL CANCER Most ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Treat Guidel Med Lett. 2006 Aug;4(48):55-60 |  Show IntroductionHide Introduction